Zydus Cadila gets USFDA nod for muscle relaxant injection
PTI, Sep 2, 2020, 3:53 PM IST
Drug firm Zydus Cadila has received final approval from the US health regulator to market Cisatracurium Besylate Injection, a muscle relaxant given before general anesthesia.
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Cisatracurium Besylate Injection USP in the strength of 20 mg (base)/10 mL (2 mg/mL) multiple-dose vial, Cadila Healthcare said in a regulatory filing on Wednesday, September 2.
The drug will be manufactured at Liva plant of Cadila Healthcare Ltd. Zydus Cadila is a part of the Cadila Healthcare group.
The group now has 297 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 377.60 apiece on BSE, 0.15 percent lower against their previous close.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
PM cautions ‘significant risk of misuse’ of AI and other powerful tech in unskilled, untrained hands
RBI announces MPC schedule for FY25, first rates decision on April 5
Seven out of ten Indian shoppers say they would happily receive product deliveries without additional packaging
Renault Nissan to launch four new products, expand product portfolio
Sensex, Nifty rebound on heavy buying in Reliance Industries, HDFC Bank
MUST WATCH
Latest Additions
PM cautions ‘significant risk of misuse’ of AI and other powerful tech in unskilled, untrained hands
Lok Sabha polls 2024: District poll panels fix varied menu, ceiling for poll expenditure
Union minister Hardeep Puri compares Sunita Kejriwal to Rabri Devi
For ‘Bhoomi Putra’ Kharge, prestigious LS poll battle in Karnataka
Special court convicts 7 people in BSP MLA Raju Pal murder case